Cargando…
Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases
INTRODUCTION: Inclusion body myositis (IBM) is a slowly progressive degenerative inflammatory disorder affecting both proximal and distal muscles. Immunosuppressive therapies are generally ineffective in the treatment of this disorder, and most patients are resistant to steroid therapy. Some benefit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649754/ https://www.ncbi.nlm.nih.gov/pubmed/26600787 http://dx.doi.org/10.1159/000441490 |
_version_ | 1782401410728460288 |
---|---|
author | Cherin, Patrick Delain, Jean-Christophe de Jaeger, Christophe Crave, Jean-Charles |
author_facet | Cherin, Patrick Delain, Jean-Christophe de Jaeger, Christophe Crave, Jean-Charles |
author_sort | Cherin, Patrick |
collection | PubMed |
description | INTRODUCTION: Inclusion body myositis (IBM) is a slowly progressive degenerative inflammatory disorder affecting both proximal and distal muscles. Immunosuppressive therapies are generally ineffective in the treatment of this disorder, and most patients are resistant to steroid therapy. Some benefits with mild improvement were observed with intravenous immunoglobulin (IVIg), particularly in patients with severe dysphagia. OBJECTIVES: The objective of this review was to describe the use of subcutaneous Ig (SCIg) in patients with IBM and to assess its feasibility. RESULTS: This report reviews 6 cases of IBM treated with SCIg in clinical practice. All patients had received prior treatments for IBM, including immunosuppressive agents and IVIg. SCIg was administered over a long period of time, ranging from 4.5 to 27 months. No patient discontinued the SCIg because of a treatment-related event or safety issues. The 6 cases showed an improvement in muscle strength and resolution of dysphagia. For 2 patients, this improvement persisted for approximately 12 months. CONCLUSIONS: SCIg might be proposed as an alternative therapy to patients with IBM who are resistant to corticoids and immunosuppressive therapies. Our findings suggest that treatment with SCIg (Gammanorm 16.5%, Octapharma AB) is feasible and safe in patients with IBM. |
format | Online Article Text |
id | pubmed-4649754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-46497542015-11-23 Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases Cherin, Patrick Delain, Jean-Christophe de Jaeger, Christophe Crave, Jean-Charles Case Rep Neurol Published online: November 2015 INTRODUCTION: Inclusion body myositis (IBM) is a slowly progressive degenerative inflammatory disorder affecting both proximal and distal muscles. Immunosuppressive therapies are generally ineffective in the treatment of this disorder, and most patients are resistant to steroid therapy. Some benefits with mild improvement were observed with intravenous immunoglobulin (IVIg), particularly in patients with severe dysphagia. OBJECTIVES: The objective of this review was to describe the use of subcutaneous Ig (SCIg) in patients with IBM and to assess its feasibility. RESULTS: This report reviews 6 cases of IBM treated with SCIg in clinical practice. All patients had received prior treatments for IBM, including immunosuppressive agents and IVIg. SCIg was administered over a long period of time, ranging from 4.5 to 27 months. No patient discontinued the SCIg because of a treatment-related event or safety issues. The 6 cases showed an improvement in muscle strength and resolution of dysphagia. For 2 patients, this improvement persisted for approximately 12 months. CONCLUSIONS: SCIg might be proposed as an alternative therapy to patients with IBM who are resistant to corticoids and immunosuppressive therapies. Our findings suggest that treatment with SCIg (Gammanorm 16.5%, Octapharma AB) is feasible and safe in patients with IBM. S. Karger AG 2015-11-05 /pmc/articles/PMC4649754/ /pubmed/26600787 http://dx.doi.org/10.1159/000441490 Text en Copyright © 2015 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Published online: November 2015 Cherin, Patrick Delain, Jean-Christophe de Jaeger, Christophe Crave, Jean-Charles Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases |
title | Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases |
title_full | Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases |
title_fullStr | Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases |
title_full_unstemmed | Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases |
title_short | Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases |
title_sort | subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases |
topic | Published online: November 2015 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649754/ https://www.ncbi.nlm.nih.gov/pubmed/26600787 http://dx.doi.org/10.1159/000441490 |
work_keys_str_mv | AT cherinpatrick subcutaneousimmunoglobulinuseininclusionbodymyositisareviewof6cases AT delainjeanchristophe subcutaneousimmunoglobulinuseininclusionbodymyositisareviewof6cases AT dejaegerchristophe subcutaneousimmunoglobulinuseininclusionbodymyositisareviewof6cases AT cravejeancharles subcutaneousimmunoglobulinuseininclusionbodymyositisareviewof6cases |